Apatinib Degrades PD-L1 and Reconstitutes Colon Cancer Microenvironment via the Regulation of Myoferlin.

Although the combination therapy group demonstrated a trend toward further slowing tumor growth compared to the apatinib monotherapy group, this difference did not reach statistical significance.

also in 111,027 other papers

The results of monotherapy with apatinib or combination therapy with apatinib and PD-1 antibodies showed a trend toward slowing tumor growth with the combination therapy, but statistical significance was not achieved.

also in 53,322 other papers